BiotechTube

Tropifexor + Licogliflozin

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Alcoholic Steatohepatitis (NASH)

Conditions

Non Alcoholic Steatohepatitis (NASH)

Trial Timeline

Dec 30, 2019 → Oct 27, 2022

NCT ID
NCT04065841

About Tropifexor + Licogliflozin

Tropifexor + Licogliflozin is a phase 2 stage product being developed by Novartis for Non Alcoholic Steatohepatitis (NASH). The current trial status is terminated. This product is registered under clinical trial identifier NCT04065841. Target conditions include Non Alcoholic Steatohepatitis (NASH).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04065841Phase 2Terminated

Competing Products

20 competing products in Non Alcoholic Steatohepatitis (NASH)

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
GODEX + PlaceboCelltrionPhase 3
77
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
Tirzepatide + PlaceboEli LillyPhase 2
52
AZD9550 + AZD9550 + PlaceboAstraZenecaPhase 1
33
AZD2693AstraZenecaPhase 1
33
placebo + Omega-3 carboxylic acids + Dapagliflozin + PlaceboAstraZenecaPhase 2
52
AZD4831AstraZenecaPhase 2
52
AZD2693AstraZenecaPhase 2
52
AZ compoundAstraZenecaPhase 2
52
cotadutide solution for injectionAstraZenecaPhase 1
33
Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placeboAstraZenecaPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85